Overview

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Status:
Recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital